Cationic liposomes-mediated plasmid DNA delivery in murine hepatitis induced by carbon tetrachloride.
In order to elucidate the influence of hepatic disease stage on cationic liposomes-mediated gene delivery, we investigated the cationic liposomes-mediated plasmid DNA delivery with time in murine hepatitis induced by subcutaneous injection of CCl(4). Liver injury after injection of CCl(4) was confirmed by the determination of serum aspartate aminotransferase and alanine aminotransferase activities. Two kinds of liposomes constructed with N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethlylammoniumchloride and dioleylphosphatidylethanolamine (DOTMA-DOPE) or DOTMA and cholesterol (DOTMA-CHOL) were used for the gene-delivery vector. We determined luciferase activities in various organs after the intravenous administration of the lipoplexes. The CCl(4)-treated mice administered with DOTMA-DOPE lipoplexes showed the more significant decreases of transgene expression in the liver and spleen at 18 hours after CCl(4) injection. On the other hand, the CCl(4)-treated mice administered with DOTMA-CHOL lipoplexes showed a significant increase in the liver at 48 hours. In conclusion, our findings demonstrate that murine hepatitis induced by CCl(4) can influence cationic liposomes-mediated plasmid DNA delivery. The extent of influences was also affected by lipid contents. These results indicate the necessity of considering the timing and the formulation for gene therapy according to the disease stage.
Yoshioka
Takashi
T
Department of Hospital Pharmacy, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki, Japan.
Yoshida
Shohei
S
Kurosaki
Tomoaki
T
Teshima
Mugen
M
Nishida
Koyo
K
Nakamura
Junzo
J
Nakashima
Mikiro
M
To
Hideto
H
Kitahara
Takashi
T
Sasaki
Hitoshi
H
D000818:Animals; D002251:Carbon Tetrachloride / Q000378:metabolism; D002252:Carbon Tetrachloride Poisoning / Q000235:genetics / Q000378:metabolism; D002412:Cations / Q000378:metabolism; D002784:Cholesterol / Q000235:genetics / Q000378:metabolism; D004247:DNA / Q000008:administration & dosage / Q000235:genetics / Q000378:metabolism*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors; D006505:Hepatitis / Q000235:genetics / Q000378:metabolism; D008055:Lipids / Q000235:genetics; D008081:Liposomes / Q000378:metabolism*; D008099:Liver / Q000378:metabolism; D008297:Male; D051379:Mice; D010714:Phosphatidylethanolamines; D010957:Plasmids / Q000378:metabolism; D000644:Quaternary Ammonium Compounds; D019076:Transgenes
C410262:1,2-dioleoyl-glycero-3-phosphatidyl ethanolamine; D002412:Cations; D008055:Lipids; D008081:Liposomes; D010714:Phosphatidylethanolamines; D000644:Quaternary Ammonium Compounds; C054005:N-(1-(2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium; D004247:DNA; D002784:Cholesterol; D002251:Carbon Tetrachloride